for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vectura Group PLC

VEC.L

Latest Trade

85.50GBp

Change

0.85(+1.00%)

Volume

3,476,219

Today's Range

84.15

 - 

86.00

52 Week Range

65.85

 - 

90.15

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
84.65
Open
84.15
Volume
3,476,219
3M AVG Volume
10.72
Today's High
86.00
Today's Low
84.15
52 Week High
90.15
52 Week Low
65.85
Shares Out (MIL)
666.30
Market Cap (MIL)
564.03
Forward P/E
17.83
Dividend (Yield %)
--

Next Event

Dividend For VEC.L - 6.0000 GBX

Latest Developments

More

Vectura Says $89.7 Mln Award To Co Related To GSK Litigation Upheld

Vectura Group Proposed Special Dividend And Share Consolidation, Share Buyback Programme And Dividend Reinvestment Plan

Vectura Group Proposes Special Dividend

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vectura Group PLC

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Industry

Biotechnology & Drugs

Contact Info

One Prospect West

+44.1249.667700

http://www.vectura.com

Executive Leadership

Bruno F. J. Angelici

Non-Executive Chairman of the Board

Paul Fry

Interim Chief Executive Officer, Chief Financial Officer, Executive Director

Joanne Hombal

Executive Vice President of Human Resources

Antony Fitzpatrick

Executive Vice President – Operations

Roger Heerman

Executive Vice President - Commercial and Business Development

Key Stats

2.00 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2016

0.1K

2017

0.1K

2018

0.2K

2019(E)

0.2K
EPS (GBp)

2016

6.740

2017

4.160

2018

3.910

2019(E)

4.747
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.27
Price To Book (MRQ)
1.18
Price To Cash Flow (TTM)
1,128.05
Total Debt To Equity (MRQ)
1.73
LT Debt To Equity (MRQ)
1.48
Return on Investment (TTM)
-13.67
Return on Equity (TTM)
-12.40

Latest News

Drugmaker Vectura parts ways with CEO Ward-Lilley

British drugmaker Vectura Group Plc's chief executive officer James Ward-Lilley will step down at the end of this month, the company said on Monday, saying it had agreed with the industry veteran that a change of leadership was needed.

Drugmaker Vectura CEO James Ward-Lilley to step down

British drugmaker Vectura Group Plc's chief executive officer, James Ward-Lilley, will step down by the end of this month, the company said on Monday.

BRIEF-Vectura Group To Receive $2.5 Mln Milestone Payment For QVM149 Submission

* WILL RECEIVE A $2.5MILLION MILESTONE PAYMENT UNDER AN EXCLUSIVE LICENCE AGREEMENT WITH NOVARTIS AG Source text for Eikon: Further company coverage:

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S

British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018.

Vectura hopes new respiratory device will breathe life into business

Vectura Group <VEC.L> is pinning its future on a relatively new respiratory device aimed at treating several ailments beyond asthma, as the British drugmaker looks to revive its business after the costly acquisition of rival SkyePharma in 2016.

UK drugmaker Vectura expects 2018 earnings to top market forecasts

British drugmaker Vectura Group Plc on Thursday predicted that its adjusted earnings in 2018 would top market expectations, helped in part by improving profit margins.

Vectura drops severe asthma treatment after poor trial results

Britain's Vectura Group Plc will stop developing its treatment for severe uncontrolled asthma after a trial showed it failed to have a significant impact on the condition.

Vectura to stop developing asthma treatment after late-stage failure

British drugmaker Vectura Group Plc said on Monday it would stop developing its treatment for severe uncontrolled asthma after the drug-device combination failed to meet the main goal of a late-stage study.

UPDATE 1-Vectura reviewing drug stockpiles as no-deal Brexit looms

British drugmaker Vectura Group Plc is reviewing its stockpiles of drugs and key components as part of its mitigation plan for a "no-deal" Brexit and warned on Tuesday of a potential disruption to supply chains and higher costs.

Vectura reviewing drug stockpiles as no-deal Brexit looms

Vectura Group Plc is reviewing its stockpiles of drugs and key components as part of its plan for a "no-deal" Brexit, the British drugmaker said on Tuesday, and warned of a potential disruption to supply chains and higher costs.

BRIEF-Sosei Says Does Not Intend To Make An Offer For Vectura

* CONFIRMS THAT IT DOES NOT INTEND TO MAKE AN OFFER FOR VECTURA

BRIEF-Vectura Says CFO Decided To Leave Group

* CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR ANDREW DERODRA HAS DECIDED TO LEAVE GROUP

Vectura posts wider 2017 loss, revenue rise

British drugmaker Vectura <VEC.L> reported a worse-than-expected pretax loss for the full year on Wednesday, dragged by lower royalties and higher costs related to the SkyePharma deal.

BRIEF-Vectura Group Posts FY Reported Revenue Of 148.0 Mln Pounds

* FULL YEAR REPORTED REVENUE OF £148.0 MILLION, IN LINE WITH BOARD EXPECTATIONS (REPORTED 9M 2016: £126.5 MILLION)

BRIEF-Vectura Group Anticipates FY 2017 Revenue In Line With Board's Expectations

* FULL YEAR 2017 REVENUE ANTICIPATED TO BE IN LINE WITH BOARD'S EXPECTATIONS

BRIEF-Vectura group announces buyback to return up to £15 million of capital to shareholders​

* vectura group plc (lse: vec) ("vectura", " group"), announces that board has approved a share buyback to return up to £15 million of capital to shareholders Source text for Eikon: Further company coverage: (Reporting by Lawrence White)

BRIEF-Vectura confident on outlook for Novartis inhaler products

* Q3 2017 net sales of $101 million for ultibro ® breezhaler ® and $37 million for seebri ® breezhaler

BRIEF-Vectura updates on positive Flutiform K-haler regulatory progress

* FLUTIFORM BREATH-ACTIVATED K-HALER MAKES POSITIVE EUROPEAN REGULATORY PROGRESS

BRIEF-Vectura Group posts HY revenue of 78.8 million pounds

* HY REVENUE 78.8 MILLION POUNDS VERSUS 73.9 MILLION POUNDS A YEAR AGO

BRIEF-Vectura signs VR410 agreement with Pulmatrix

* PROGRESSING DEVELOPMENT OF BRANDED GENERIC TIOTROPIUM BROMIDE PROGRAMME (VR410) FOR US MARKET, ACCELERATED THROUGH LICENCE DEAL WITH PULMATRIX

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up